Soralimixin
Soralimixin (BRII-693), a Polymyxin derivative, is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic. Soralimixin can be used for the study of infections caused by drug-resistant Gram-negative pathogens.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 1814918-91-6
- Fòrmula: C48H80Cl2N16O13
- Peso molecular:1160.15
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
Descripciòn
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1814918-91-6
-
Peso molecular 1160.15
-
Fòrmula C48H80Cl2N16O13
-
Synonyms
BRII-693; QPX9003
-
Sequence
{Dab(2,4-dichlorobenzaldehyde)}-{Thr}-{Dpr}-{Dab}-{Dab}-{d-Leu}-{Abu}-{Dab}-{Dab}-{Thr} (Lactam bridge: Dab4-Thr10)
-
Sequence Shortening
{Dab(2,4-dichlorobenzaldehyde)}-{Thr}-{Dpr}-{Dab}-{Dab}-{d-Leu}-{Abu}-{Dab}-{Dab}-{Thr} (Lactam bridge: Dab4-Thr10)
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Watkins M, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of a synthetic macrocyclic peptide antibiotic (BRII-693) in healthy adult participants. Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0128824. [Content Brief]
[2]. Iovleva A, et al. Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections. Drugs. 2025 Jan;85(1):21-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)